Ignite Creation Date:
2024-05-06 @ 9:28 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02988843
Status:
TERMINATED
Last Update Posted:
2020-12-10
First Post:
2016-12-01
Brief Title:
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Organization Data
Organization:
Masonic Cancer Center University of Minnesota
Class:
OTHER
Study ID:
2015LS190
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Masonic Cancer Center University of Minnesota
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None